Industry Newsnovel drugsbiopharmaceuticalsnmpareimbursement policy
China Expands Novel-Drug Approvals And Reimbursement
7.3
In 2025 China's National Medical Products Administration approved a record 76 innovative drugs, officials said, up from 48 in 2024. The approvals, combined with regulatory reforms since 2015 and the addition of new therapies to the 2026 national reimbursement list, have lowered patient costs and driven $135.7 billion in out-licensing deals in 2025, signaling rising domestic biopharma influence globally.
Key Points
- 1Approves 76 innovative drugs in 2025, record high, with about 80–90% domestically manufactured
- 2Reforms since 2015 introduced priority review, conditional approvals and expedited pathways accelerating development
- 3Enables broader patient access via 2026 national reimbursement inclusion and boosts lucrative out‑licensing revenues
Scoring Rationale
Record approvals, regulatory reform and large out‑licensing illustrate substantial industry impact; limited AI/DS relevance reduces cross-domain effect.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
